A Single-Center, Randomized, Double-Blind, Single and Multiple Ascending-Dose, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics (Including the Effect of Food) and Pharmacodynamics of RO5508887 Following Oral Administration in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 10 Jun 2016
At a glance
- Drugs RG 7129 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Roche
- 19 Sep 2012 Planned End Date changed from 1 Feb 2012 to 1 Sep 2012 as reported by ClinicalTrials.gov.
- 15 Feb 2012 Actual patient number (50) added as reported by ClinicalTrials.gov.
- 15 Feb 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.